Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Unmet needs in the treatment of T-cell malignancies

Swaminathan Iyer • 10 Jun 2022
EHA 2022
Cutaneous T-Cell Lymphoma Lymphoma T-Cell Lymphoma Antibodies Brentuximab vedotin Mogamulizumab
COBALT-LYM ECHELON-2

Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses unmet needs in T-cell lymphoma, highlighting the limited treatment options available for patients and the need to improve options for patients with relapsed disease, who generally have a poor outcome. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE

More from Swaminathan Iyer

3:17
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer • 11 Dec 2023
2:39
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer • 11 Dec 2023
5:32
A machine learning model to analyze histopathological tissue in DLBCL
Swaminathan Iyer • 11 Dec 2023
2:57
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer • 11 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals